The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen

Cancer Letters

Volumn 229, Issue 2, 2005, Pages 193-204

  Stiborová, Marie ^a   Sopko, Bruno ^a   Hodek, Petr ^a   Frei, Eva ^b   Schmeiser, Heinz H ^b   Hudeček, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Aristolochic acid; Carcinogen; Computer modeling; Cytochromes P450 1A1 and 1A2, reductive activation; DNA adduct; Docking; Urothelial cancer

Indexed keywords

7 (DEOXYADENOSIN N6 YL)ARISTOLACTAM I; 7 (DEOXYADENOSIN N6 YL)ARISTOLACTAM II; 7 (DEOXYGUANOSIN N2 YL)ARISTOLACTAM I; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; ARISTOLOLACTAM; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; PHOSPHORUS 32; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CRYSTALLOGRAPHY; DNA ADDUCT; DNA BINDING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; KIDNEY PARENCHYMA; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ARISTOLOCHIC ACIDS; BINDING SITES; CARCINOGENS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; HUMANS; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PROTEIN BINDING; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

MAMMALIA;

EID: 26444446947     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.038     Document Type: Article

References (58)

1. J.L. Vanherweghem, M. Depierreux, C. Tielemans, D. Abramowicz, M. Dratwa, and M. Jadoul Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs Lancet 341 1993 387 391
2. M. Vanhaelen, R. Vanhaelen-Fastre, P. But, and J.L. Vanherweghem Identification of aristolochic acid in Chinese herbs Lancet 343 1993 174
3. M. Vanhaelen, J.J. Cuykens, Ph. Vandenberg, K.P. Bouman, and Y. Hagens Valvular heart disease and Chinese-herbs nephropathy Lancet 351 1998 991
4. M.-C. Martinez, J. Nortier, P. Vereestaeten, and J.L. Vanherweghem Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose Nephrol. Dial. Transpl. 17 2002 408 412
5. J.-P. Cosyns Aristolochic acid and 'Chinese Herbs nephtopathy'. A review if the evidence to date Drug Saf. 26 2003 33 48
6. V.M. Arlt, M. Stiborová, and H.H. Schmeiser Aristolochic acid as a probable cancer hazard in herbal remedie: a review Mutagenesis 17 2002 265 277
7. G. Gillerot, M. Jadoul, V.M. Arlt, C. van Ypersele de Strihou, H.H. Schmeiser, and P.H.H. But Aristolochic acid nephropathy in a Chinese patient: time to abandon the term 'Chinese herbs nephropathy'? Am. J. Kidney Dis. 38 2001 E26
8. K. Solez, J. Daugirdes, M.C. Gregory, P.P. Frohnert, D.M. Blownik, and V. Iha Is 'Chinese herbs nephropathy' a prejudical term? Am. J. Kidney Dis. 38 2001 1141 1142
9. J.-P. Cosyns, M. Jadoul, J.P. Squifflet, F.X. Wese, and C. van Ypersele de Strihou Urothelial lesions in Chinese-herb nephropathy Am. J. Kidney Dis. 33 1999 1011 1017
10. J.L. Nortier, M. Muniz Martinez, H.H. Schmeiser, V.M. Arlt, C.A. Bieler, and M. Petein Urothelial carcinoma associated with the use of a Chinese herb ({i}Aristolochia fangchi{/i}) N. Engl. J. Med. 342 2000 1686 1692
11. G.M. Lord, T. Cook, V.M. Arlt, H.H. Schmeiser, G. Williams, and C.D. Pusey Urothelial malignancy and Chinese herbal nephropathy Lancet 358 2001 1515 1516
12. M. Ivic The problem of etiology of endemic nephropathy Acta. Fac. Med. Naiss. 1 1970 29 37
13. C.A. Tatu, W.H. Oren, R.B. Finkelman, and G.L. Feder The etiology of Balkan endemic nephropathy: still more questions than answers Environ. Health Perspect. 106 1998 689 700
14. V.M. Arlt, D. Ferluga, M. Stiborová, A. Pfohl-Leskowicz, M. Vukelic, and S. Ceovic Is aristolochic acid a risk for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer 101 2002 500 502
15. A. Pfohl-Leskowicz, T. Petkova-Bocharova, I.N. Chernozemsky, and M. Castegnaro Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins Food Addit. Contam. 19 2002 282 302
16. IARC Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene vol. 82 2002 International Agency for Research on Cancer Lyon
17. H.H. Schmeiser, K.-B. Schoepe, M. Wiessler, and D.N.A. adduct formation of aristolochic acid I and II in vitro and in vivo Carcinogenesis 9 1988 297 303
18. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II Carcinogenesis 11 1990 1627 1633
19. 32P-postlabeling analysis using different chromatographic procedures Carcinogenesis 15 1994 1187 1192
20. H.H. Schmeiser, C.A. Bieler, M. Wiessler, C. van Ypersele de Strihou, and J.-P. Cosyns Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy Cancer Res. 56 1996 2025 2028
21. 32P-post-labeling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy Carcinogenesis 18 1997 1063 1067
22. M. Stiborová, E. Frei, A. Breuer, C.A. Bieler, and H.H. Schmeiser Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy Exp. Toxic. Pathol. 51 1999 421 427
23. V.M. Arlt, A. Pfohl-Leszkowicz, J-P. Cosyns, and H.H. Schmeiser Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy Mutat. Res. 494 2001 143 150
24. H.H. Schmeiser, J.W.G. Janssen, J. Lyons, H.R. Scherf, W. Pfau, and A. Buchmann Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues Cancer Res. 50 1990 5464 5469
25. V.M. Arlt, M. Wiessler, and H.H. Schmeiser Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene Carcinogenesis 21 2000 235 242
26. V.M. Arlt, H.H. Schmeiser, and G.P. Pfeifer Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR Carcinogenesis 22 2001 133 140
27. G.M. Lord, M. Hollstein, V.M. Arlt, C. Roufosse, C.D. Pusey, T. Cook, and H.H. Schmeiser DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy Am. J. Kidney Dis. 43 2004 Art.No.e11
28. G. Smith, L.A. Stanley, E. Sim, R.C. Strange, and R. Wolf Metabolic polymorphism and cancer susceptibility Cancer Surv. 25 1995 27 65
29. 32P-post-labeling: evidence for reductive activation by peroxidases Carcinogenesis 18 1997 1055 1062
30. 32P-postlabeling analysis of DNA adduct formation Mutat. Res. 493 2001 153 164
31. M. Stiborová, E. Frei, M. Wiessler, and H.H. Schmeiser Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochrome P450 1A1 and 1A2 Chem. Res. Toxicol. 14 2001 1128 1137
32. M. Stiborová, E. Frei, M. Hájek, and H.H. Schmeiser Carcinogenic and nephrotoxic aristolochic acids upon activation by NADPH: cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy Gen. Physiol. Biophys. 20 2001 375 392
33. M. Stiborová, E. Frei, B. Sopko, M. Wiessler, and H.H. Schmeiser Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy Carcinogenesis 23 2002 617 625
34. M. Stiborová, E. Frei, B. Sopko, K. Sopková, V. Marková, and M. Laňková Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H: quinone oxidoreductase Carcinogenesis 24 2003 1695 1703
35. M. Stiborová, E. Frei, P. Hodek, M. Wiessler, and H.H. Schmeiser Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH: CYP reductase and prostaglandin H synthase mediate the formation of aristolochic acid DNA-adducts found in patients with urothelial cancer Int. J. Cancer 113 2005 189 197
36. H.H. Schmeiser, B.L. Pool, and M. Wiessler Mutagenicity of the two main components of commercially available carcinogenic aristolochic acids in Salmonella typhimurium Cancer Lett. 23 1984 107 111
37. 32P-postlabeling test for structurally diverse DNA adducts Carcinogenesis 7 1986 1543 1551
38. M.R. Wester, E.F. Johnson, C. Marques-Soares, S. Dijols, P.M. Dansette, and D. Mansuy Structure of mammalian cytochrome P4502C5 complexed with diclofenac at 2.1 angstrom resolution: evidence for an induced fit model of substrate binding Biochemistry 42 2003 9335 9345
39. G.A. Schoch, J.K. Yano, M.R. Wester, K.J. Griffin, C.D. Stout, and E.F. Johnson Structure of human microsomal cytochrome P4502C8 - evidence for a peripheral fatty acid binding site J. Biol. Chem. 279 2004 9497 9503
40. M.R. Wester, J.K. Yano, G.A. Schoch, C. Yang, K.J. Griffin, and C.D. Stout The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution J. Biol. Chem. 279 2004 35630 35637
41. E.E. Scott, M.A. White, Y.A. He, E.F. Johnson, C.D. Stout, and J.R. Halpert Structure of mammalian cytochrome P4502B4 complexed with 4-(4-chlorophenyl) imidazole at 1.9-angstrom resolution - insight into the range of P450 conformations and the coordination of redox partner binding J. Biol. Chem. 279 2004 27294 27301
42. P.A. Williams, J. Cosme, D.M. Vinkovic, A. Ward, H.C. Angove, and P.J. Day Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone Science 305 2004 683 686
43. S.F. Altschul, W. Gish, W. Miller, E.W. Myers, and D.J. Lipman Basic local alignment search tool J. Mol. Biol. 215 1990 403 410
44. A. Sali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restrains J. Mol. Biol. 234 1999 779 815
45. A. Fiser, R.K. Do, and A. Sali Modeling of loops in protein structures Protein Sci. 9 2000 1753 1773
46. J.D. Thompson, T.J. Gibson, F. Plewniak, F. Jeanmougin, and D.G. Hiffins The CLUSTAL X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools Nucleic Acids Res. 25 1997 4876 4882
47. N. Guex, and M.C. Peitsch SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling Electrophoresis 18 1997 2714 2723
48. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, and R.K. Belew Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comp. Chem. 19 1998 1639 1662
49. B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, and M. Karplus CHARMM: a program for macromolecular energy, minimization, and dynamics calculations J. Comput. Chem. 4 1983 187 217
50. R.A. Laskowski, M.W. MacArthur, D.S. Moss, and J.M. Thornton PROCHECK - a program to check the stereochemical quality of protein structure J. Appl. Cryst. 26 1993 183 191
51. P. Dauber-Osguthorpe, V.A. Roberts, D.J. Osguthorpe, J. Wolff, M. Genest, and A.T. Hagier Structure and energetics of ligand binding to protein: Escherichia coli dihydrofolate reductase-trimethoprim, a drug receptor system Proteins 4 1988 31 47
52. A. Williams, J. Cosme, V. Sridhar, E.F. Johson, and D.E. McRee Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity Mol. Cell 5 2000 121 131
53. D.F. Lewis Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure Xenobiotica 32 2002 305 323
54. Y.-H. Chae, T. Thomas, F.P. Guengerich, P.P. Fu, and K. El-Bayoumy Comparative metabolism of 1-, 2-, and 4-nitropyrene by human hepatic and pulmonary microsomes Cancer Res. 59 1999 1473 1480
55. V.M. Arlt, M. Stiborova, A. Hewer, H.H. Schmeiser, and D.H. Phillips Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH: cytochrome P450 reductase Cancer Res. 63 2003 2752 2761
56. F.P. Guengerich Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes Chem. Res. Toxicol. 4 1991 391 407
57. S. Rendic, and F.J. DiCarlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab. Rev. 29 1997 413 480
58. M. Stiborová, E. Frei, and H.H. Schmeiser Identification of human enzymatic systems activating carcinogenic alkaloid aristolochic acid in vitro Chem. Listy 93 1999 723 724